<DOC>
	<DOCNO>NCT02345174</DOCNO>
	<brief_summary>Human epidermal growth factor receptor 3 ( HER3 ) expression see across wide variety solid malignancy associate poor prognosis . Up-regulation HER3 expression activity also associate resistance multiple pathway inhibitor . GSK2849330 , monoclonal antibody ( mAb ) target HER3 , new agent subject whose tumor express HER3 . This study aim characterise biodistribution dose-receptor occupancy relationship GSK2849330 patient advance HER3 express solid tumour via use PET imaging . This study conduct two part . Part 1 image phase subject receive two dos GSK2849330 contain Zirconium-89 ( 89Zr ) label GSK2849330 unlabeled GSK2849330 . The amount unlabeled GSK2849330 present dose varied explore effect target mediate uptake 89Zr HER3 express tissue tumor . Subjects proceed continuation phase ( Part 2 ) continue treatment unlabelled GSK2849330 . The study plan enroll approximately 12-15 subject .</brief_summary>
	<brief_title>Immuno Positron Emission Tomography Study GSK2849330 Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Males females &gt; =18 year age ( time consent obtain ) . Written inform consent provide . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Sufficient archival tumor specimen available HER3 immunohistochemistry ( IHC ) analysis , subject willing undergo tumor biopsy HER3 IHC analysis . Subjects must tumours documented HER3 expression cell surface ( 1+ , 2+ 3+ ) invasive component tumour ( either archival tissue fresh biopsy ) use analytically validate IHC assay central laboratory . Histologically cytologically confirm diagnosis solid tumour malignancy standard therapeutic alternative exist . Adequate baseline organ function Left ventricular ejection fraction ( LVEF ) &gt; =50 % Echocardiogram ( ECHO ) Multi gate acquisition scan ( MUGA ) . Subjects must least two measurable lesion Computed tomography ( CT ) Magnetic resonance imaging ( MRI ) scan short axis least 20 millimeter ( mm ) . Subjects leptomeningeal brain metastasis spinal cord compression Prior HER3 direct treatment ( HER2 EGFRdirected treatment acceptable ) . Unresolved toxicity great National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , version 4.0 Grade 1 previous anticancer therapy Known suspect hypersensitivity reaction prior biologic therapy Evidence another active malignancy ( excludes nonmelanoma skin cancer ) . Concurrent medical condition would jeopardize compliance protocol . Receiving concurrent antitumor therapy , chronic immunosuppressive therapy ( include daily steroid dos excess 20 milligram ( mg ) /day prednisolone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>zirconium</keyword>
	<keyword>oncology</keyword>
	<keyword>mAb</keyword>
	<keyword>receptor occupancy</keyword>
	<keyword>dose</keyword>
	<keyword>PET</keyword>
	<keyword>HER3</keyword>
	<keyword>89-Zr</keyword>
	<keyword>biodistribution</keyword>
	<keyword>tumour</keyword>
</DOC>